brilaroxazine (RP5063) / Reviva 
Welcome,         Profile    Billing    Logout  

2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
brilaroxazine (RP5063) / Reviva
2021-004193-64: A Study to assess the effectivenss of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia.

Not yet recruiting
3
402
Europe
Brilaroxazine, RP5063, Tablet
Reviva Pharmaceuticals Holdings Inc., Reviva Pharmaceuticals Holdings Inc.
Acute Exacerbation of Schizophrenia, Schizophrenia, Psychiatry and Psychology [F] - Mental Disorders [F03]
 
 
RECOVER, NCT05184335: Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Recruiting
3
402
US
Brilaroxazine, RP5063, Placebo
Reviva Pharmaceuticals
Schizophrenia
10/24
10/24

Download Options